Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191141 | 0.90 | BRD4 (0.39) | BRD4RORCPDE4DPDE4APDE4B | |
| SCHEMBL21190895 | 0.90 | BRD4 (0.45) | BRD4RORCPDE4DPDE4APDE4B | |
| SCHEMBL21190902 | 0.87 | BRD4 (0.49) | BRD4MMP13 | |
| SCHEMBL22647802 | 0.83 | BRD4 (0.36) | BRD4 | |
| SCHEMBL21190880 | 0.83 | TBK1 (0.41) | BRD4RORCPDE4DPDE4APDE4B | |
| SCHEMBL21191042 | 0.81 | BRD4 (0.51) | BRD4 | |
| SCHEMBL21190869 | 0.80 | BRD4 (0.47) | BRD4PDE4ASYKTBK1KAT2B | |
| SCHEMBL21190849 | 0.80 | BRD4 (0.44) | BRD4RORCPDE4DPDE4APDE4B | |
| SCHEMBL21191020 | 0.78 | BRD4 (0.52) | BRD4RORCPDE4DPDE4APDE4B | |
| SCHEMBL16658429 | 0.78 | BRD4 (0.38) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885RORC 253/4885PDE4D 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.